Skip to main content


Cardiovascular Drugs and Therapy

Cardiovascular Drugs and Therapy OnlineFirst articles

15.02.2020 | Original Article Open Access

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

Transthyretin-mediated amyloidosis (ATTR amyloidosis) is a rapidly progressing, life-threatening disease caused by misfolded transthyretin (TTR) protein that deposits as amyloid fibrils in multiple organs [ 1 – 3 ]. In hereditary TTR-mediated …

15.02.2020 | Original Article

A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y12 Receptor

Platelets play essential roles in clotting and hemostasis, and when activated in some pathologic conditions such as atherosclerosis, they promote the formation of occlusive thrombi which may result in myocardial infarction and stroke [ 1 ]. The …

15.02.2020 | Original Article Open Access

Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes

Patients suffering acute coronary syndromes (ACS) are routinely treated with dual antiplatelet therapy (DAPT) consisting of aspirin and an adenosine diphosphate (ADP) P2Y 12 antagonist for 12 months to prevent detrimental platelet activation and …

15.02.2020 | Editorial

The British Society for Cardiovascular Research Autumn 2019 Meeting Incorporating the Bernard and Joan Marshall Research Awards

15.02.2020 | Review Article Open Access

The Role of Extracellular DNA and Histones in Ischaemia-Reperfusion Injury of the Myocardium

Despite an increase in the rates of survival in patients suffering myocardial infarction, as yet there is no therapy specifically targeting ischaemia and reperfusion injury of the myocardium. With a greater understanding of immune activation …

Aktuelle Ausgaben

Über diese Zeitschrift

Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

Five Reasons to Publish Your Article in Cardiovascular Drugs and Therapy:

· High usage: Articles frequently downloaded from month to month

· Wide distribution: Institutions worldwide having full text access

· Efficient handling: 18 days between submission and first decision

· Fast publication: 17 days between acceptance and online publication

· International readership: North America, Asia, Europe, Middle East and South America

Weitere Informationen

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.